Precision Psychiatry: Is Genetic Testing the Future of Mental Health?

For decades, psychiatric diagnosis has relied primarily on clinical observation—what a doctor sees and hears in the room. While this “symptom-based” approach has helped millions, it often misses the underlying biological “blueprints” that dictate how a patient will respond to treatment. Today, genetic analysis is bridging that gap.

Where We Are Now: Pharmacogenomics

Currently, the most beneficial application of genetics in psychiatry is pharmacogenomics (PGx). Rather than diagnosing the condition itself, these tests analyze how your liver enzymes (such as \bm{CYP2D6} and \bm{CYP2C19}) metabolize specific medications.

• The Benefit Today: PGx testing helps identify “ultra-rapid” or “poor” metabolizers. This allows us to avoid medications that might cause severe side effects or fail to reach therapeutic levels, significantly shortening the time it takes to find the right treatment.

The Diagnostic Frontier: Genetic Signatures

While we cannot yet diagnose “Depression” or “Bipolar Disorder” with a single DNA swab, the science is evolving rapidly. Recent 2025 and 2026 landmark studies have identified shared genetic signatures across 14 major psychiatric disorders. We now know that conditions like Schizophrenia and Bipolar Disorder share up to 70% of their genetic risk factors.

How Soon Before It’s Routine?

• 1–3 Years: Integration of “polygenic risk scores” to help clinicians differentiate between similar-looking conditions (e.g., Unipolar vs. Bipolar Depression).

• 5+ Years: The emergence of “biotype” diagnosing, where treatments are prescribed based on specific biological pathways (like excitatory neuron function) rather than traditional diagnostic labels.

At the practice of Mark Agresti, MD, we stay at the forefront of these advancements to ensure your treatment plan is as unique as your DNA.